The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics, treatment patterns, and outcomes of HIV-associated lung cancer.
 
Tina Roy
No Relationships to Disclose
 
Ujjwal Karki
No Relationships to Disclose
 
Tianzhi Tang
No Relationships to Disclose
 
Anya Gupta
No Relationships to Disclose
 
Kanchi Krishnamurthy
Stock and Other Ownership Interests - Multiple pharmaceutical companies and mutual funds (I)
 
Camelia Bencheqroun
No Relationships to Disclose
 
Jia Li Dong
No Relationships to Disclose
 
Joan Mattle
Employment - CHS Mobile Integrated Healthcare (I)
 
Maryam Abdussamad
No Relationships to Disclose
 
Samir Gupta
No Relationships to Disclose
 
Shuo Wang
No Relationships to Disclose
 
Subha Jamal
Employment - Georgetown Univ.
Honoraria - Georgetown Univ.
 
Joshua Reuss
Honoraria - Merck
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Catalym; Daiichi Sankyo; Gilead Sciences; Janssen; Lilly; Merck; Novocure; Pfizer; Regeneron; Seagen; Signatera; Summit Therapeutics
Research Funding - Arcus Biosciences (Inst); Exelixis (Inst); Genentech/Roche (Inst); Nuvalent, Inc. (Inst); Verastem (Inst)
 
Jaeil Ahn
Consulting or Advisory Role - KeifeRx
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merus; Mirati Therapeutics; MSD Oncology; Natera; Novartis; OSE Immunotherapeutics; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Systimmune (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Marta Catalfamo
No Relationships to Disclose
 
Adil Alaoui
No Relationships to Disclose
 
Chul Kim
Consulting or Advisory Role - Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Onviv; Pinetree; Regeneron; Sanofi; Takeda
Research Funding - AstraZeneca; Black Diamond Therapeutics; Boehringer Ingelheim; Daiichi Sankyo; Genentech/Roche; Gilead Sciences; Janssen; Lyell Immunopharma; Macrogenics; Novartis; ORIC Pharmaceuticals; Regeneron